Prime Medicine, Inc.

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo

In the top alliance by deal value, Prime Medicine and Bristol Myers Squibb teamed up to develop reagents for multiple next-generation, ex vivo CAR-T cell therapies in immunology and oncology. Prime

Next-generation gene editing company Prime Medicine has signed a research partnership with Bristol Myers Squibb to work on ex vivo T-cell therapies, providing it with some much-needed cash and a

The idea of manipulating biology to produce therapeutics is not new. In 1978, Eli Lilly and Company and Genentech, Inc. developed the first recombinant DNA human insulin by inserting the human gen